Evidence map›Paper›PMID 39563717›Full record

ArticleTherapeutic advances in medical oncology2024

Changes in alpha-fetoprotein across the systemic therapy continuum in advanced hepatocellular carcinoma-a real-world, multicenter study.

Michael Li, Lindsay M Hannan, Lipika Goyal, Andrea G Bocobo, Anna L Parks, Kelly Bauer, Islam Baiev, Caroline Dinicola, John D Gordan, Alan P Venook and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Therapeutic advances in medical oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Michael LiDivision of Gastroenterology and Hepatology, Department of Medicine, University of California, San Francisco. 513 Parnassus Ave, S-357, San Francisco, CA 94143, USA.ORCID https://orcid.org/0000-0003-0836-811X
Lindsay M HannanUniversity of Washington Medical Center, Seattle, WA, USA.
Lipika GoyalMassachusetts General Hospital, Boston, MA, USA.
Andrea G BocoboUniversity of California, San Francisco, San Francisco, CA, USA.
Anna L ParksUniversity of California, San Francisco, San Francisco, CA, USA.
Kelly BauerUniversity of California, San Francisco, San Francisco, CA, USA.
Islam BaievMassachusetts General Hospital, Boston, MA, USA.
Caroline DinicolaMassachusetts General Hospital, Boston, MA, USA.
John D GordanUniversity of California, San Francisco, San Francisco, CA, USA.
Alan P VenookUniversity of California, San Francisco, San Francisco, CA, USA.
William P HarrisUniversity of Washington Medical Center, Seattle, WA, USA.
Paige BracciUniversity of California, San Francisco, San Francisco, CA, USA.
Robin K KelleyDivision of Hematology and Oncology, Department of Medicine, University of California, 550 16th Street, Rm 6532, San Francisco, CA 94158, USA.

Funding

Advancing patient-centered decision making in older adults with venous thromboembolismK76AG083304 · NIA · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Anna L Parks · 2024 to 2026
$729k
NIA NIH HHS K76 AG083304
6 · The paper itself

Abstract

Background: Early changes in alpha-fetoprotein (AFP) are a promising surrogate endpoint for systemic treatment outcomes in hepatocellular carcinoma (HCC). Objectives: We sought to investigate the utility of AFP response across first-line sorafenib (1L SOR) and later-line checkpoint inhibitor (CPI) therapies. Design: We conducted a multicenter, retrospective cohort study of patients with advanced HCC who received 1L SOR and any subsequent CPI. Methods: The primary outcomes were overall survival (OS) and time on treatment (TOT). Pre-treatment AFP and the lowest AFP within 3 months of treatment initiation were used to calculate the percent change in AFP for each treatment. AFP response was defined as an AFP reduction by ⩾20% within 3 months, and AFP progression was defined as an increase in AFP by ⩾20% within 3 months. Patients with baseline AFP < 20 ng/mL were considered not evaluable for AFP change. Results: Of 176 study patients, 46 (28%) received CPI after SOR, and 125 (71%) had a baseline AFP ⩾ 20. Patients who experienced AFP response on SOR had significantly longer OS and TOT than those who did not and those who were not evaluable (OS: median 689 vs 320 vs 452 days, log-rank Conclusion: Early AFP response with 1L SOR and any subsequent CPI was associated with longer OS and TOT, and early AFP progression was associated with shorter OS and TOT. These data support utilizing longitudinal AFP changes as a surrogate endpoint in HCC systemic therapy.

Indexed as

checkpoint inhibitoroverall survivalsorafenibtime on treatment

Identifiers

PMID39563717
PMCPMC11574907

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.